MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
192 M |
Market Cap[1] |
$ 14.2 B |
EBITDA (LTM) |
$ -361 M |
P/E (LTM) |
-23.333333 |
P/S (LTM) |
14.32091 |
EPS (LTM) |
-3.03 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Agenus
AGEN
|
$ 6.42 | -7.89 % | $ 191 M | Nasdaq Capital Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.11 | -9.52 % | $ 3.32 B | Nasdaq Global Select Market |  Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.12 | -8.77 % | $ 401 K | Nasdaq Global Select Market | USA |
 |
Immatics N.V.
IMTX
|
$ 6.2 | -10.35 % | $ 759 M | Nasdaq Global Select Market |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.24 | -9.49 % | $ 391 K | Nasdaq Capital Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.58 | -8.76 % | $ 45.3 M | Nasdaq Global Select Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.62 | -1.63 % | $ 444 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 26.8 | 0.32 % | $ 4.07 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.16 | -6.1 % | $ 3.03 M | Nasdaq Capital Market | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.31 | -16.3 % | $ 192 M | Nasdaq Global Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.6 | -3.64 % | $ 400 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.55 | -1.68 % | $ 1.29 B | Nasdaq Global Select Market | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market |  China |
 |
Aquestive Therapeutics
AQST
|
$ 3.66 | -3.82 % | $ 391 M | Nasdaq Global Market | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -19.71 % | $ 933 K | Nasdaq Capital Market | USA |
 |
Arvinas
ARVN
|
$ 6.56 | -11.66 % | $ 465 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.13 | -12.01 % | $ 406 M | Nasdaq Global Market | USA |
 |
Beam Therapeutics
BEAM
|
$ 25.84 | -7.03 % | $ 2.56 B | Nasdaq Global Select Market | USA |
 |
Moderna
MRNA
|
$ 241.1 | -6.69 % | $ 93.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Fortress Biotech
FBIO
|
$ 1.83 | -7.11 % | $ 51.1 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 80.4 | -7.34 % | $ 3.79 B | Nasdaq Global Select Market | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.0 | -3.54 % | $ 139 M | Nasdaq Capital Market |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 22.52 | -1.1 % | $ 8.3 B | Nasdaq Global Select Market | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.14 | -8.94 % | $ 295 M | Nasdaq Global Select Market | USA |
 |
Krystal Biotech
KRYS
|
$ 300.08 | -3.46 % | $ 8.69 B | Nasdaq Global Market,SPB | USA |
 |
Kura Oncology
KURA
|
$ 6.93 | -9.0 % | $ 608 M | Nasdaq Global Select Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.45 | -7.67 % | $ 143 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.28 | -6.8 % | $ 46.7 M | Nasdaq Global Select Market,SPB | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 1.45 | -10.8 % | $ 68 M | Nasdaq Global Select Market | USA |
 |
Corvus Pharmaceuticals
CRVS
|
$ 9.73 | -7.95 % | $ 768 M | Nasdaq Global Market | USA |
 |
Aytu BioScience
AYTU
|
$ 1.83 | -4.69 % | $ 22.5 M | Nasdaq Capital Market | USA |
 |
Heat Biologics, Inc.
HTBX
|
- | -5.76 % | $ 99.8 M | Nasdaq Capital Market | USA |
 |
Innoviva
INVA
|
$ 19.23 | -9.57 % | $ 1.3 B | Nasdaq Global Select Market | USA |
 |
BioCardia
BCDA
|
$ 0.9 | -1.43 % | $ 6 M | Nasdaq Global Select Market | USA |
 |
Kindred Biosciences, Inc.
KIN
|
- | 0.11 % | $ 419 M | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.28 | -6.56 % | $ 14.6 B | Nasdaq Capital Market |  Australia |
 |
Shineco, Inc.
TYHT
|
- | -3.90 % | $ 97.2 M | Nasdaq Global Select Market | China |
 |
Millendo Therapeutics, Inc.
MLND
|
- | -5.36 % | $ 20.2 M | Nasdaq Global Select Market | USA |
 |
Certara
CERT
|
$ 12.05 | 8.61 % | $ 1.93 B | Nasdaq Global Select Market | USA |
 |
Dyadic International
DYAI
|
$ 0.34 | -7.09 % | $ 12.3 M | Nasdaq Capital Market | USA |
 |
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M | Nasdaq Capital Market | Israel |
 |
Anika Therapeutics
ANIK
|
$ 19.29 | -5.44 % | $ 277 M | Nasdaq Global Select Market,SPB | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.5 | -1.96 % | $ 3.27 M | Nasdaq Global Select Market,SPB | USA |
 |
Galectin Therapeutics
GALT
|
$ 2.98 | -14.12 % | $ 190 M | Nasdaq Global Select Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 71.75 | -9.43 % | $ 7.45 B | Nasdaq Capital Market,SPB | USA |
 |
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | Nasdaq Global Select Market | USA |
 |
Genprex
GNPX
|
$ 2.09 | -2.34 % | $ 1.95 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.